The Idea for Production of a Novel Narrow Spectrum Covid-19 Drug

Yohanis Irenius Mandik

Department of Chemistry, Faculty of Mathematics and Natural Sciences, Cenderawasih University, Jalan Kamp Walker, Jayapura 99358, Indonesia

Email: <u>yimandik@gmail.com</u>

Abstract

Most drugs used in current medication for Covid-19 patient indicate several side effects due to the broad-spectrum drugs that affect the whole cells of human body (infected and healthy cells). Antiviral such as enzyme inhibitors, dideoxy, nucleoside/nucleotide analogs, amino acid analogs, even single chemical compound such as chloroquine phosphate, carboxylic acid type drugs and similar drugs may suppress some key molecules and changed pH not only in reactions which related to virus but also inevitably in the whole cells of human body. Based on all facts, then I designed the less cells destroying method to inhibit specifically SARS-CoV-2 replication in human cells. Since the sequence of single strand positive sense of SARS-CoV-2 has determined, the mechanism of its replication inside human lung cells was also well understood, the transport membrane (endocytosis) of oligonucleotides are well known and the supportive biotechnological methods are adequate to produce this type of drug then I proposed this methods and design respectively: 1) Study the specific sequence of SARS-CoV-2 RNA. 2) Synthesize the oligonucleotide using nucleotides analogs (to produce fake primers) that can specifically attach to the specific sequence of SARS-CoV-2 RNA. 3) Conduct in vitro experiments using the fake primers produced and the infected cells, study the efficiency of endocytosis of fake primers through cell membrane and to know the best dosage that can inhibit the SARS-CoV-2 replication. 4) Conduct clinical tests to the Covid-19 patients based on the *in vitro* test results (after passing the ethics protocol). So, the proposed novel narrow spectrum drug is the fake primer produced.

Keywords: Covid-19, Fake primer, Narrow spectrum drug

INTRODUCTION

Currently, the drugs and vaccines that have been used and been developing for medication of Covid 19 patients are mostly based on broad spectrum drugs that effect both infected cells and healthy cells. The broad-spectrum drugs also produce some metabolites that could give negative effect to metabolism then leads to several symptoms and diseases. The utilization of broad spectrum drugs

inevitably generate several side effects to patient because some drugs based on monomer such as nucleotide/ nucleoside analogs, dideoxynucleotide/ dideoxynucleoside, amino acid analogs, single chemical compound drugs (carboxylic acids. Chloroquine phosphate, etc.), and enzymes inhibitors. Those types of drugs mostly effect many biochemical reactions in not only reactions which related to the virus but also the whole cells of human body. The drugs could not avoid to be involved in transcriptions, translations, replications, production, all enzymatic enzymes reactions in metabolism, biosynthesis of biomolecules in the whole cells of human body due to each of their function as biomolecules precursor in biosynthesis. The pH changes to be more alkaline also occur in all cells not only in the infected Besides that, a single type of cells. monomer used such as nucleotide analog tends to cause fatal mutation by its end products in both infected cells and healthy cells.

Meanwhile, the vaccines which have been developing and the fact that SARS-Cov-2 viruses have been mutating from Type A to Type B, then to Type C and predictably will continue mutating due to the lack of proof reading mechanism during transcription process of the virus RNA. Some drugs also based on chemical molecule such as several types of carboxylic acid that responsible to inhibit specific reaction in virus before released from host cells exhibited several side effects to patient due to its metabolites produced in the cells. Therefore this short communication of review article aimed to propose a new method for designing and producing a novel narrow spectrum Covid-19 drug that will specifically react only inside the infected cells, relatively be more specific then predictably would reduce the side effects to the patients.

METHODS

This research was conducted by using literature review method. The results of this study were concluded as a Proposed Idea which can be used by all researchers who have been developing Covid-19 Drugs.

LITERATURE REVIEW

1. Structure of Coronaviruses

Coronaviruses (CoVs) are single stranded RNA viruses that are included in the Coronavirinae subfamily, the Coronavirdiae family. the order of Nidovirales, which is surrounded protein envelope. CoV can be divided into four genes, namely, Alphacoronavirus (αCoV), Betacoronavirus (β CoV), Deltacoronavirus (δCoV) , and Gammacoronavirus (γCoV). This group of viruses originates from zoonoses with αCoV and βCoV commonly found in bats and mice, while generally δCoV and γCoV are found in poultry species (Chan et al, 2013). The Coronaviruses have

spike proteins which mediates membrane fusion to bind to the cellular receptors (Figure 1). envelope creating a crown-like appearance (Chan *et al*, 2013).




Figure 1. Structure of Coronaviruses (Source: Cascella et al, 2020)

CoV-2 SARS virus is а betacoronavirus which was firstly revealed in Wuhan City, Hubei Province, China in December 2019 (Li et al, 2020). It contains four structural proteins, namely Spike (S), Envelope (E), Membrane (M). and Nucleocapside (N). The envelope of SARS CoV-2 was built from proteins S, M, and E. The M protein is the most responsible protein for the shape of the envelope. The E protein is the smallest structural protein. The S and M proteins are important during replication, while the N proteins responsible for the formation of nucleocapside in the envelope. The N proteins are also involved in the viral infection through assembly and budding of the CoV replication cycle. In addition, the name Coronavirus comes from the S proteins which surrounded the

2. Genomic structure of SARS-CoV-2

The genome of SARS-CoV-2 is a single-stranded positive-sense RNA of 30kb (29891 nucleotides) encoding 9860 amino acids. The G + C content is 38%. The organization of SARS CoV-2 consists of 12 open reading frames (ORFs), one set of nine sub genomic mRNAs, nine transcriptionregulatory parts, and 2 terminal regions which are untranslated. The first ORF contain almost two-thirds of the viral RNA that translates two polyproteins and encodes 16 non-structural proteins (NSP). The remaining ORFs encode structural (S, E, M, N) and accessory proteins (Perlman et al, 2009). In terms of whole genome sequence, it is revealed that SARS CoV-2 is closer to the SARS-like bat coronavirus (Chan et al,

2020). Nevertheless, mutations are found in NSP2, NSP3, and S proteins, which determined the infectious capability and replication mechanism of SARS CoV-2 (Angeletti *et al*, 2020).

COVID-19 infection is severe pneumonia, together with acute cardiac injury (Cascella *et al*, 2020).




Figure 2. Genome structure of Coronaviruses (Source: Cascella et al, 2020)

3. Mechanisms of SARS-CoV-2 infection

There are three ways of SARS-CoV-2 transmission: droplets, contact, and aerosol transmissions (Figure 3). Droplets transmission can occur when infected patients cough, or sneeze and the droplets are inhaled or ingested by other people nearby. Contact transmission can occur when a person touches the surface or object which previously contaminated with the virus, and afterwards touches his eyes, mouth. Meanwhile, aerosol or nose. transmission can occur when droplets mix into the air and forming aerosol which is then inhaled in high dose into the lungs of nearby people. The main pathogenesis of

The incubation period of SARS-CoV-2 infection ranges from 1 day to 14 days, which is also associated with the age of the infected people (Li et al, 2020). Age of 60 and above usually has incubation period faster compared with others. After the virus enter the respiratory tract, it affects the alveoli. The epithelial cells in the lower respiratory tract helps the virus to attach to receptor, hACE2. which its is downregulated after the infection of SARS-CoV-2. The binding of SARS-CoV-2 S protein is believed to be the virulence key factor for viral attachment and entry.

structural and non-structural proteins responsible for viral RNA synthesis, the socalled replicase-transcriptase proteins. These replicase-transcriptase proteins are encoded in ORF1a and ORF1b which synthesized as pp1a and pp1ab.




Figure 3. Transmission cycle of SARS-CoV-2 (Source: Cascella et al, 2020)

The S protein and hACE2 binding efficiency in SARS-CoV-2 infection is 10-20-fold higher than that of SARS-CoV infection. However, which molecules facilitate the membrane of SARS-CoV-2 endocytosis are still unclear. The S protein comprises S1 and S2 subunits. The subunit S1 is responsible for the binding via Receptor Binding Domain (RBD), while the subunit S2 helps the fusion of virus-cell membrane (Song *et al*, 2018).

The genome RNA of CoV contains about 30kb nucleotides which encodes

NSP1 to NSP11 are encoded in ORF1a, while NSP12 to NSP16 are encoded in ORF1b. The complex of replicasetranscriptase (RTC) protein is composed of replicase-transcriptase protein together with other viral proteins and cellular proteins. This RTC is associated with doublemembrane vesicles. The NSP3, NSP6, and NSP6 are the anchor of pp1a/pp1ab to membranes during the first step of RTC formation (Perlman and Netland, 2009). The virion-containing vesicles fuse with the plasma membrane of the cell and release the

virus which subsequently attach a new cell. So, the replication cycle is repeated.

4. Current Treatments

Drugs and Vaccines that currently used to fight the Covid-19 pandemic as seen in Figure 4.

TREATMENTS					
Drug	Company	Target	Slage	Treatment Goal	Location
A Restrict Opproach - (Second)	- Annule	THEY DESIGNATION AND INCOME.	COLUMN TWO IS NOT	Annual growth	
a. Amoni	C Pharefulatilierit	Including and the and the set	COLUMN STREET,	And what growth	- 60
3 General Dimension	C Aschette	Heigt CA-Dy partitions		Trial proversions	•
Accession	C Fastoer Derapeutics	recondurant turnerunet		Anto-officereneitery	
S-Artenia	Reste	Sine Infoldation		Anti-Inflammatory	- 60
C.Lentinenski	Harrakingen	anti-ten cor		Auto-Inflamounting	
7. Chinele	General menune	E-s intribution		Anti-Inflammatory	
- Contraction	Children Public Heatth	HPV-1 proteiner erfelluter + CVPsA velokister		Titled Sciences of the	
St. Cold Victor	Contraction research in subscript	Endbolier (Interruptions)		Anti-Indianiniality	
10. diment	Collegeartis, Decyle	phar annelisation	Contraction in the local division in the loc	Treat provenancia	
11-045mm	Annen Bropherma	chimment tradic actual		Anti-weat provide	000
12-Charlent	 Intellig 	spatially manufacture	Contraction (Section	Blinck wood areity total and	
13-Trickphard	- Valde Phermaceuticals	Many united allow		Anti-tofter states	
14.mercara	Pergeriseries, Santali	R. w. and application	C	Auto influence along	
15. Orienteent	C Lines of Monsteiller	ALL-CONTRACTOR		Ann-what prowth	•
The longest	C Fueldam	THE payments in the second		Anti-stal growth-	
17. Admitter	Roome	wide annutation		Treat prevenionia	- 65
12-101-	 Inflation 	Calmile		Auto Inflammalary	-
19. Noveret	a state	B-Industry		Auto-Inflamonationy	- The second sec
20. tarritare	- Canal	University .		Anti-Information	
28. Remainstrate	C Grant	adentificities interiorg			000
22 teronimuti (PRO seci-	Cytabye	COTI and against	Comment of the Party of the	Auto Indumentation's	0
23. Automotiv	- henertafte	B-services		Avel-telfamonatory	- a
24. Stiller	C Trymalityjers	ITTL MENA-MA	Contract Contract	Treat respiratory lines.	- a
25 Correct	horadia	spherogeneral to promphate receptor modulidator		Amounters	
26. Referie	Southeast Lines, Onnet	PG-semilator		Treat presentoxia/segret	
27. APRIL	O APPENDIA BARAGAN	International Section Party		Anti-weat provide a	+-
28. P.J041	C Harming C	and the second s	_	Present East.	•
29. Alverer telefonometal	Constant Pasters Same	PRIMA CONTROLOGICA		Publi-un al growth	00
10 Calmana	Can-Pile Bloghamma	As an entropy of a second		Anti-Inflammatory	
all chartered	C ELGA Pharma	To a constitutor		And a collision stations	
33 Veller	Etite	and a subject to the	Concession of Concession	Trust presences	- 1
33. UIG-1004	O Depart	MARCHINE Induktion	Concession in the local division in the loca	Topal Impublic direct	
34 Crimes	Conservy	had card thereater	C President	Anti-vital growth,	5
35. Ideases/Aprend Silvers Collin	CANDID Call & Game	Time represention	-	And in the second star of	
38-District	C Riermenstudy Lävise. 10	Intern continent	CORRECTION	Towar improveduities Towar preserve	
Street States 194	Number State	CARE HALL	Statement of the local division of the local		
37. Menuetation	Terra Dio Mongritan	anti-CDigs antibusts	C.Builting	Design processing	
36-base-ban	City of Monwella	ATC DOD		Fielduce project tall in the	1
19. Constant	Revent	#41.00 CSF	Contraction of the local division of the loc	Anti-Inflammatory	12
49 Convenient Plante Weinage	Multiple Locations	and hotbur hotes elemented policenty.	Emergency Line. Are 1 kiewicer	Auti-scal prowth,	Contra Contra

Figure 4. Several treatments of Covid-19 (Source: Artis Ventures, 2020)

RESULTS AND DISCUSSIONS

Since the mechanism of SARS-Cov-2 replication was well understood and also mostly the supportive biotechnology methods are sufficient to sequence the virus RNA, the availability of nucleotides analog, the technique to synthesis oligonucleotide as primer, then the fake primer that synthesis by using nucleotides analog can be produced. Moreover, the transport membrane and endocytosis of oligonucleotides were also known for up taking and trafficking of oligonucleotide in cytoplasm. Therefore, the fake primers produced would be the new drugs for Covid-19 patients.

The idea of using fake primer as the drug for Covid-19 patients based on following mechanism (Figure 5):




Figure 5. (a). Viruses inject their RNA to cytosol of human lung cell. (b) Fake primer (oligonucleotide analog) attach to the virus RNA. (c) Fake primers attach to viruses RNAs then will stop the working of RNA dependent RNA polymerase inside the infected cell. (d) So, the new virions will not be formed.

The virus RNA which has an attached fake primer will not be processed further to produce vital protein for new virions. The aggregate of RNA and fake primer then naturally destroyed by cell's mechanism.

CONCLUSIONS

I proposed the methods and design respectively: 1) Study the specific sequence of SARS-CoV-2 RNA. 2) Synthesize the oligonucleotide using nucleotides analogs (to produce fake primers) that can specifically attach to the specific sequence of SARS-CoV-2 RNA. 3) Conduct in vitro experiments using the fake primers produced and the infected cells, study the efficiency of endocytosis of fake primers through cell membrane and to know the best dosage that can inhibit the SARS-CoV-2 replication. 4) Conduct clinical tests (after passing the ethics protocol) to the Covid-19 patients based on the *in vitro* test results. So, the proposed novel narrow spectrum drug is the fake primer.

REFERENCES

Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M, 2020. COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis. Journal of medical virology. doi: 10.1002/jmv.25719.

- Artis Ventures, available from <u>https://www.av.co/covid-treatments</u>
- Cascella M, Rajnik M, Cuomo A, et al. 2020. Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Apr 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from:

https://www.ncbi.nlm.nih.gov/books/ NBK554776/.

- Chan JF,Kok KH,Zhu Z,Chu H.To KK,Yuan S,Yuen KY, 2020. Genomic characterization of the novel human-pathogenic 2019 coronavirus isolated from a patient atypical pneumonia with after visiting Wuhan. Emerging microbes, 9(1):221-236.
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM *et al*, 2020. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine. 382(13):1199-1207.
- Perlman S, Netland J, 2009. Coronaviruses post-SARS: update on replication

and pathogenesis. Nature reviews. Microbiology. 7(6):439-50.

Song W,Gui M,Wang X,Xiang Y, 2018. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS pathogens. 14(8):e10072